In This Article:
Cristina Arias / Cover / Getty Images
Johnson & Johnson (JNJ) on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year.
The pharmaceutical and medical technology firm posted adjusted earnings per share (EPS) of $2.77 on revenue of $21.89 billion. Analysts had expected $2.56 and $21.56 billion, respectively, according to estimates compiled by Visible Alpha.
Johnson & Johnson shares were down about 0.6% shortly after the market opened. They entered the day up about 7% since the start of the year.
The company lifted its projected operating sales range to $91.0 billion to $91.8 billion, up from $89.2 billion to $90.0 billion previously. It also held its adjusted EPS forecast steady at $10.50 to $10.70, "including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange."
CFO Says J&J Expects $400M in 2025 Tariff Costs
CFO Joseph Wolk said on CNBC following the report's release that Johnson & Johnson expects tariff costs of roughly $400 million this year. The company also announced that it will increase its quarterly dividend to $1.30 per share from $1.24 previously, marking 63 straight years that it has raised its dividend.
Since reporting a disappointing 2025 sales outlook in January, the company closed its nearly $15 billion acquisition of Intra-Cellular Therapies and announced plans to lift its U.S. investment to more than $55 billion over the next four years.
Johnson & Johnson stock slipped earlier this month after a judge rejected its proposed "prepackaged bankruptcy plan" for a subsidiary that would settle thousands of claims alleging its talc products caused cancer.
UPDATE—This article has been updated with the latest share price information, along with details from CFO Joseph Wolk's CNBC appearance and the company's new dividend.
Read the original article on Investopedia